Previous studies have confirmed the relative safety of anti-PD-1/PD-L1 agents, but the primary drug resistance rate to PD-1/PD-L1 is as high as 60% in patients with malignant tumors such as OSCC (Topalian et al., 2012). This evidence concerns the gene PDCD1 and cancer.